Abstract:Introduction: Pemphigus vulgaris (PV) is an autoimmune disease characterized by IgG autoantibodies targeting desmoglein-3 (Dsg3), leading to blistering of mucous membranes and skin. Although commercial ELISA kits effectively diagnose PV, correlation with clinical phenotype remains unclear. This study assesses multiple panels for monitoring disease severity and activity by profiling IgG autoantibodies against Dsg3's various extracellular ectodomains. Method: We designed and expressed different extracellular domains of Dsg3 in HEK293T cell line and developed 15 different ELISA panels, each using a single or multi ectodomains encompassing the entire extracellular region of Dsg3 to detect specific autoantibodies against the particular part of Dsg3. Results: To validate our approach, we compared our ELISA panel for the full Dsg3 (EC1-5) against a commercial kit using 154 random serum samples from PV patients, demonstrating a strong correlation. For evaluation of IgG autoantibody profiles in our panels, 59 PV patients were included, along with 11 bullous pemphigoid patients, and 49 healthy controls. For all the included subjects, 15 predefined ELISA panels were tested. The IgG autoantibodies against EC1 were detected in 86% of patients with a positive full Dsg3 ectodomain (EC1-5) ELISA, with 26% against EC2, 14% for EC3, 29% for EC4, and 23% for EC5. Among the panels with multiple Dsg3 ectodomains, EC1-3 and EC1-4 were representative of the entire Dsg3 ectodomain in terms of ELISA positivity across all included patients. A significant correlation (P<0.05) was observed between ELISA optical density (OD) and Pemphigus Disease Area Index (PDAI) scores in five panels, EC1, EC2-3, EC2-5, and EC3-4 in addition to the full ectodomain. It suggests an association with disease severity. Interestingly, while the ELISA panel for the entire Dsg3 extracellular ectodomains did not differentiate disease phases, in three of our panels, including EC1, EC3-5, and EC2-5, ANOVA analysis showed a statistically significant difference between the groups of patients in remission, partial remission or persistent lesions, and those with active disease (new cases or relapse). Among these three panels, EC1 was the only one that showed a significant difference in the multiple comparisons analysis; patients in the active phase had higher levels of autoantibodies than those in 'partial remission or persistent lesions' and 'complete remission' groups. Conclusion: The level of autoantibodies against EC1 was not only correlated with the full ectodomain but also associated with higher disease severity and active disease phase. This study indicates that a detailed autoantibody profile against Dsg3 ectodomains could serve as a marker for PV severity and activity which may potentially enhance early treatment initiation.

Pathogenic relevance of antibodies against desmoglein 3 in patients with oral lichen planus

Detection of anti-desmoglein antibodies in oral lichen planus: What do we know so far

013 Semaphrin4D Drives CD8+ T Cells Skin Trafficking in Oral Lichen Planus Via CXCL9 and CXCL10 Upregulations in Oral Keratinocytes

Protein Disulfide Isomerase Family A Member 3 Expression is Upregulated in Tissue-Derived Extracellular Vesicles in Oral Lichen Planus and Oral Lichenoid Lesions.

Langerhans Cells, T Cells, and B Cells in Oral Lichen Planus and Oral Leukoplakia

Pathogenic Igg Antibodies Against Desmoglein 3 in Pemphigus Vulgaris Are Regulated by Hla-Drb1*04:02-Restricted T Cells

Pathogenic IgG Antibodies Against Desmoglein 3 in Pemphigus Vulgaris Are Regulated by HLA-DRB1*04:02–Restricted T Cells

Direct immunofluorescence and immune function in patients with oral lichen planus

Autoimmunity and epithelial dysplasia in patients with oral lichenoid diseases

Upregulation of Anti-Desmocollin 3 Antibodies in Pemphigus Diseases: A Case-control Study

Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells.

Modulation of desmoglein-3-specific T cell response and pathogenic antibody generation in mice.

Evaluation of the Role of Oral Microbes in Pathogenesis of Oral Lichen Planus

Expression of Programmed Death Ligand 1 and Indoleamine 2,3‐Dioxygenase in Oral Lichen Planus and Oral Lichenoid Lesions

Epitope analysis of antidesmoglein 1 autoantibodies from patients with pemphigus foliaceus across different activity stages

Analysis of oral microbial community and Th17-associated cytokines in saliva of patients with oral lichen planus

Clinical, Histological and Direct Immunofluorescence Features in Oral Mucosal Patches Striae Diseases with Malignant Potential

Single-cell immune profiling reveals immune responses in oral lichen planus

IgG reactivity to different desmoglein-3 ectodomains in pemphigus vulgaris: novel panels for assessing disease severity

Immunophenotypic and Gene Expression Analyses of the Inflammatory Microenvironment in High-Grade Oral Epithelial Dysplasia and Oral Lichen Planus

Increased Infiltration of CD11 C+/cd123+ Dendritic Cell Subsets and Upregulation of TLR/IFN-α Signaling Participate in Pathogenesis of Oral Lichen Planus.